Letter to the Editor: COVID-19,Mitochondria,and Interferon

Blanco-Melo D , Nilsson-Payant BE , Liu W , Uhl S , Hoagland D , Møller R , Jordan TX , Oishi K , Panis M , Sachs D , Wang TT , Schwartz RE , Lim JK , Albrecht RA , TenOever BR . 2020. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 181:1–10.

Dong L , Hu S , Gao J . 2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther, 14:58–60.

Greenberg SB . 2016. Update on human rhinovirus and coronavirus infections. Semin Respir Crit Care Med, 37:555–571.

Refolo G , Vescovo T , Piacentini M , Fimia GM , Ciccosanti F .2020. Mitochondrial interactome: a focus on antiviral signaling pathways. Front Cell Dev Biol 8:8.

Shi CS , Qi HY , Boularan C , Huang NN , Abu-Asab M , Shelhamer JH , Kehrl JH . 2014. SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome. J Immunol, 193:3080–3089.

Srinivasan S , Cui H , Gao Z , Liu M , Lu S , Mkandawire W , Narykov O , Sun M , Korkin D . 2020. Structural genomics of SARS-CoV-2 indicates evolutionary conserved functional regions of viral proteins. Viruses, 12:e360.

Stockman LJ , Bellamy R , Garner P . 2006. SARS: systematic review of treatment effects. PLoS Med, 3:e343.